ADVERTISEMENT

Clinical Summary

Renal cancer: a review of survival benefit with immune checkpoint inhibitors

Deepa Koli   |   23 November 2022

A systematic review of immune checkpoint inhibitor (ICI) combinations for advanced renal cancer finds that treatment with ICIs has a significant survival benefit over the tyrosine kinase inhibitor (TKI) sunitinib. The combination treatment should be made readily available worldwide to patients with advanced renal cell carcinoma (RCC), the authors said.

Until...

          

Topic Challenges

left
right